Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, Planned Parenthood Mar Monte, San Jose, and FPA Women's Health, Sacramento, California.

Corresponding author: Mitchell D. Creinin, MD, University of California, Davis, Sacramento, CA; email: mdcreinin@ucdavis.edu.

Supported by the Society of Family Planning Research Fund.

Financial Disclosure Mitchell D. Creinin is a consultant for Danco Laboratories, providing medical consultation for clinicians that contact Danco with questions regarding mifepristone. Laura Dalton is an employee of Planned Parenthood. The other author did not report any potential conflicts of interest.

The authors thank the staff and physicians at the study centers for assisting with referral and conduct of the clinical trial.

The findings and conclusions expressed in this article are those of the authors and do not necessarily reflect the views of Planned Parenthood Federation of America, Inc. or FPA Women's Health.

Each author has confirmed compliance with the journal's requirements for authorship.

Peer reviews are available at http://links.lww.com/AOG/B659.